Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel - the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients in draft guidelines.
The PharmaTimes Sales Awards closes for entry in just a few weeks and with Sanofi, Allergan, LEO Pharma, Novartis and Bio Products Laboratory and many more besides signed up to take part, all signs are pointing to a very exciting debut indeed. It only takes a few seconds to fill out the online entry form and entrants need not do anything else until the day of the competition.
With the importance of MSLs, scientific advisors and medical information professionals growing year on year - PharmaTimes Media has recognised this burgeoning area and gathered together an array of experts within the field to devise a challenging and rewarding competition that now includes seven categories.
The prestigious PharmaTimes Marketer of the Year competition closes for entries on 1 September. It only takes a few seconds to fill out the online entry form and then you don’t need to do anything else until the day of the competition. This year is extra special as the competition is celebrating its 25th anniversary - and we don't want you to miss out.
Teva and Regeneron Pharmaceuticals have unveiled positive topline results from a Phase III study assessing the safety and efficacy of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.
Researchers have discovered that a class of drugs being developed to treat cancer can also help prompt liver regeneration after severe injury, raising hopes of a new treatment that might help some patients avoid a liver transplant.